Congenital Transmission of Lineages I & II of Trypanosoma Cruzi

Status Completed

Clinical Trial Summary

T. cruzi has been divided into two main lineages: T. cruzi I (TcI) and T. cruzi II (TcII, including all non-TcI). TcI is predominant in Mexico and Central America, while TcII (non-TcI) is predominant in most of South America, including Argentina. In recent studies from Argentina, the risk of congenital transmission has been estimated to vary between 2.6 percent and 7.9 percent. By contrast, we know very little about the congenital transmission of TcI. It has been suggested that congenital transmission of T. cruzi is strain related, and there is an urgent need to know if TcI transmits differently than TcII (non-TcI). Our primary hypothesis is that congenital transmission rates are different for TcI versus TcII. Our secondary hypothesis is that the characteristics of T. cruzi infected mothers (e.g., age, parity, transmission in previous pregnancies) and their exposure to vectors are different in regions where TcI is predominant versus regions where TcII (non-TcI) is predominant. To test these hypotheses, we propose to conduct a prospective study to enroll at delivery 13,000 women in Mexico, 7,500 women in Honduras, and 10,000 women in Argentina. We will measure transmitted maternal T. cruzi antibodies in cord blood, and, if the results are positive, we will identify infants who are congenitally infected by performing parasitological examinations on cord blood and at 4-8 weeks, and serological follow-up at 10 months. We will also perform standard PCR, real-time quantitative PCR, and T. cruzi genotyping on maternal blood, standard PCR and T. cruzi genotyping on the cord blood of congenitally infected newborns, and serological examinations on siblings. We will estimate the exposure to vectors in the household. In addition, we will measure prenatal outcomes among infected and uninfected infants with seropositive mothers, and the birth weight of their siblings. The specific aims of this study are: 1) To determine the rate of congenital transmission of TcI compared to TcII (non-TcI); 2) To compare the T. cruzi infected mothers' characteristics and exposure to vectors in regions where TcI is predominant and regions where TcII (non-TcI) is predominant; and 3) To describe the birth outcomes of infected and uninfected infants born to TcI and TcII seropositive women.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Chagas Disease

Clinical Trial Details

NCT number	NCT01787968
Study type	Observational
Source	Tulane University
Contact
Status	Completed
Phase	N/A
Start date	April 2011
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01162967` - Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole	Phase 2
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Active, not recruiting	`NCT04024163` - Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease	Phase 3
Recruiting	`NCT05868005` - Delivering a Multi-disease Screening Tool to Migrant Populations	N/A
Completed	`NCT03892213` - Pharmacokinetic Drug-Drug Interaction Study	Phase 1
Recruiting	`NCT00875173` - Selenium Treatment and Chagasic Cardiopathy (STCC)	Phase 3
Recruiting	`NCT03704181` - Colchicine for Patients With Chagas´ Disease( B1 Stage)	Phase 2
Active, not recruiting	`NCT03378661` - BENDITA BEnznidazole New Doses Improved Treatment and Associations	Phase 2
Completed	`NCT01927224` - Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients	Phase 1
Completed	`NCT01006486` - Outcomes of an Anticoagulation Clinic in an University Hospital	Phase 4
Completed	`NCT00123916` - BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease	Phase 3
Completed	`NCT02516293` - Cardiac Rehabilitation in Chagas Heart Failure	Phase 2/Phase 3
Completed	`NCT02517632` - Physical Exercise Program in Chronic Chagas Heart Disease	Phase 3
Recruiting	`NCT02099903` - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease	N/A
Completed	`NCT01874795` - Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure	N/A
Completed	`NCT01006473` - Exercise Training in Chagas Cardiomyopathy	Phase 4
Completed	`NCT02386358` - Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial	Phase 3
Not yet recruiting	`NCT05477953` - An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
Completed	`NCT02346123` - Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy	N/A
Recruiting	`NCT02295215` - Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Congenital Transmission of Lineages I and II of Trypanosoma Cruzi

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms